baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UC WAR. CALL 09/24 SNW/ DE000HD5WFX1 /

2024-07-17 3:45:32 PM	Chg.-0.0100	Bid4:51:09 PM	Ask4:51:09 PM	Underlying	Strike price	Expiration date	Option type
0.1600EUR	-5.88%	- Bid Size: 175,000	- Ask Size: 175,000	SANOFI SA INHABER ...	98.00 -	2024-09-18	Call

GlobeNewswire 06-28 Verve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Di...

TeleTrader 06-27 Europe opens mixed before consumer confidence data

GlobeNewswire 06-27 Vigil Neuroscience Announces $40 Million Strategic Investment from Sanofi

GlobeNewswire 06-26 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...

GlobeNewswire 06-26 Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic e...

GlobeNewswire 06-21 Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s ...

GlobeNewswire 06-21 Press Release: ISTH: Sanofi advances leadership in hemophilia with new data for ALTUVIIIO and fitusi...

GlobeNewswire 06-20 Press Release: Sanofi and Biovac spearhead polio vaccine manufacturing capabilities in Africa

GlobeNewswire 06-18 Belharra Therapeutics Announces Strategic Collaboration with Sanofi to Advance Discovery of Novel Sm...

GlobeNewswire 06-11 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...

GlobeNewswire 06-03 Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival ...

GlobeNewswire 05-31 Press Release: Sanofi launches 2024 global Employee Stock Purchase Plan

GlobeNewswire 05-31 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 05-31 Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD

GlobeNewswire 05-31 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...

GlobeNewswire 05-31 Press Release: Update on FDA priority review of Dupixent for the treatment of COPD patients with typ...

GlobeNewswire 05-30 Press Release: Sanofi completes acquisition of Inhibrx, Inc.

GlobeNewswire 05-27 Press Release: Sarclisa accepted for FDA priority review for the treatment of transplant-ineligible ...

GlobeNewswire 05-23 CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments

GlobeNewswire 05-21 Press Release: Sanofi, Formation Bio and OpenAI announce first-in-class AI collaboration

GlobeNewswire 05-20 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...

GlobeNewswire 05-20 Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...

GlobeNewswire 05-20 Shah Capital Withdraws Proxy Campaign Against Re-Election of Directors at Novavax’s 2024 Annual Meet...

GlobeNewswire 05-13 Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 20...

GlobeNewswire 05-13 Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...

UC WAR. CALL 09/24 SNW/ DE000HD5WFX1 /

If you wish to receive reply to your feedback, please provide your email address.